American Heart Journal
Volume 146, Issue 2 , Pages 213-214 , August 2003

Percutaneous coronary interventions in patients with renal insufficiency: a high-risk, under-studied cohort

  • Steven R. Steinhubl, MD

      Affiliations

    • University of North Carolina, Chapel Hill, NC, USA
    • Corresponding Author InformationReprint requests: Steven R. Steinhubl, MD, Associate Professor of Medicine, University of North Carolina, CB#7075, Chapel Hill, NC 27599-7075, USA.

References 

  1. Szczech LA, Best PJ, Crowley E, et al.  Outcomes of patients with chronic renal insufficiency in the Bypass Angioplasty Revascularization Investigation. Circulation. 2002;105:2253–2258
  2. Rubenstein MH, Harrell LC, Sheynberg BV, et al.  Are patients with renal failure good candidates for percutaneous coronary revascularization in the new device era?. Circulation. 2000;102:2966–2972
  3. Best PJM, Lennon R, Ting HH, et al.  The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol. 2002;39:1113–1119
  4. Dacey LJ, Liu JY, Braxton JH, et al.  Long-term survival of dialysis patients after coronary bypass grafting. Ann Thorac Surg. 2002;74:458–462
  5. Masoudi FA, Plomondon ME, Magid DJ, Sales AE, Rumsfeld JS. Renal dysfunction and mortality after acute coronary syndromes [abstract]. Circulation 2002;106(2 Suppl):II-401
  6. Jones CA, McQuillan GM, Kusek JW, et al.  Serum creatinine levels in the US population (third National Health and Nutrition Examination Survey). Am J Kidney Dis. 1998;32:992–999
  7. Ting HH, Tahirkheli NK, Berger PB, et al.  Evaluation of long-term survival after successful percutaneous coronary intervention among patients with chronic renal failure. Am J Cardiol. 2001;87:630–633
  8. Anderson KM, Califf RM, Stone GW, et al.  Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol. 2001;37:2059–2065
  9. Bhatt DL, Marso SP, Lincoff AM, et al.  Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol. 2000;35:922–928
  10. Tamberella M, Bhatt D, Chew D, et al.  Relation of platelet inactivation with intravenous glycoprotein IIb/IIIa antagonists to major bleeding (from the GOLD Study). Am J Cardiol. 2002;89:1429–1431
  11. Steinhubl S, Talley J, Braden G, et al.  Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event following percutaneous coronary intervention. Results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation. 2001;103:1403–1409
  12. Reddan DN, O’Shea JC, Sarembock IJ, et al.  Treatment effects of eptifibatide in planned coronary stent implantation in patients with chronic kidney disease (ESPRIT Trial). Am J Cardiol. 2003;91:17–21
  13. Noris M, Remuzzi G. Uremic bleeding (Closing the circle after 30 years of controversies?). Blood. 1999;94:2569–2574
  14. Best PJM Lennon R, Gersh BJ, et al. Safety of abciximab in patients with chronic renal insufficiency who are undergoing percutaneous coronary intervention. Am Heart J 2003;146:345–50
  15. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet. 1998;352:87–92
  16. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 1997;336:1689–1696
  17. Jeremias A, Bhatt DL, Chew DP, et al.  Safety of abciximab during percutaneous coronary intervention in patients with chronic renal insufficiency. Am J Cardiol. 2002;89:1209–1211

PII: S0002-8703(03)00232-1

doi: 10.1016/S0002-8703(03)00232-1

American Heart Journal
Volume 146, Issue 2 , Pages 213-214 , August 2003

Article Tools